War Paint to Bone Paint: MIT Spinout Aims to Transform Regenerative Meds
Summary
Driven by 20 years in the military, the CEO of Theradaptive hopes his firm’s regenerative “paint” technology platform can transform bone repair, spinal fusion, and sports medicine. “Our approach takes protein sequences that we discover using a lab-based test and optimizes them in several ways using our computational processes,” CEO Luis Alvarez (pictured below) told this publication. “During my time in Iraq, I witnessed service members who suffered traumatic injuries undergo amputations weeks or months after the initial wound, because there was no reliable method for regenerating the bone,” he said. Theradaptive’s tech is being implemented to establish a best-in-class product pipeline in bone repair, spinal fusion, and sports medicine, tapping into a potential market worth $80 billion, according to the firm. Additional licensing opportunities are being sought to allow the firm to pursue in-house programs in soft tissue repair, and localized therapeutics.
Classifications
AskAI Classifications
LabelsLinked Companies
